In this case, the extracellular adenosine generated by exosomes expressing CD39 and CD73 interferes with antitumor immune responses, and thus, CD39 and CD73 inhibition effects have been studied for their possible clinical application against cancer [52,53]. Here, ENTPD1 is linked to cancer.